A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 26, Issue 1, 2013, Pages 38-42

  Benjamin, Mina M ^a   Filardo, Giovanni ^a   Donsky, Michael S ^a   Schussler, Jeffrey M ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; FEMALE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE;

EID: 84874106704     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12008     Document Type: Article

References (23)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.
2. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. New England J Med 1998; 339: 1665-1671. (Pubitemid 28550691)
3. Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, et al. Ticlopidine-induced aplastic anemia: Two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol 2002; 71: 24-32. (Pubitemid 34988582)
4. Taniuchi M, Kurz HI, Lasala JM,. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104: 539-543. (Pubitemid 32738122)
5. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533. (Pubitemid 32772726)
6. White HD, Ohman EM, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008; 52: 807-814.
7. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420. (Pubitemid 35340537)
8. van der Heijden DJ, Westendorp IC, Riezebos Rk, et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol 2004; 44: 20-24. (Pubitemid 38968449)
9. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: A multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-1701.
10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-e304.
11. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
12. Bernlochner I, Morath T, Brown PB, et al. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets 2012 [Epub ahead of print].
13. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009; 373: 723-731.
14. Serebruany VL,. Timing of thienopyridine loading and outcomes in the TRITON trial: The FDA Prasugrel Action Package outlook. Cardiovasc Revascular Med: Including Mol Interv 2011; 12: 94-98.
15. Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007; 99: 349-352. (Pubitemid 46149552)
16. Banerjee S, Varghese C, Samuel J, et al. Comparison of the impact of short (<1 year) and long-term (> or = 1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008; 102: 1159-1162.
17. Heeg BM, Peters RJ, Botteman M, et al. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. PharmacoEconomics. 2007; 25: 769-782. (Pubitemid 47481641)
18. Elliott RA, Shinogle JA, Peele P, et al. Understanding medication compliance and persistence from an economics perspective. Value Health: J Int Soc Pharmacoecon Outcomes Res 2008; 11: 600-610. (Pubitemid 352032815)
19. Taira DA, Wong KS, Fresh-Tamas F, et al. Copayment level and compliance with antihypertensive medication: Analysis and policy implications for managed care. Am J Managed Care 2006; 12: 678-683. (Pubitemid 44748394)
20. Khosravi AR, Pourmoghadas M, Ostovan M, et al. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study. J Res Med Sci: Off J Isfahan Univ Med Sci 2011; 16: 640-650.
21. Jeong YH, Koh JS, Kang MK, et al. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: Results of the ACCEL-GENERIC study. Korean J Int Med 2010; 25: 154-161.
22. Angiolillo DJ, Saucedo JF, Deraad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: Results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010; 56: 1017-1023.
23. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59 (24): 2159-2164.